biostudies-literatureUnknown33(24)Ciprotti M<h4>Purpose</h4>CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake, and antitumor response in patients with metastatic colorectal cancer (mCRC).<h4>Patients and methods</h4>Patients with mCRC who had received at least one course of chemotherapy were assigned to one of five dosage cohorts and infused with a weekly dose of CS-1008. Day 1 and day 36 doses were trace-labeled with indium-111 ((111)In), followed by whole-body planar and regional single-photon emission computed tomography (SPECT) imaging at several time points over the course of 10 days.<h4>Results</h4>Nineteen patients were enrolled. (111)InJournal of clinical oncology : official journal of the American Society of Clinical Oncology2609-16https://www.ebi.ac.uk/biostudies/studies/S-EPMC4881374biostudies-literaturePhase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.PMC4881374Matsumura MGreenberg JScott AMChong GBeckman RAScott FEHopkins WLee FTVenhaus RKotsuma MMcKee DCGong SJCiprotti MO'Keefe GJChappell BLee STTebbutt NCBrechbiel MWTse ANWatanabe RGan HKJansen MfalsePhase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.<h4>Purpose</h4>CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake, and antitumor response in patients with metastatic colorectal cancer (mCRC).<h4>Patients and methods</h4>Patients with mCRC who had received at least one course of chemotherapy were assigned to one of five dosage cohorts and infused with a weekly dose of CS-1008. Day 1 and day 36 doses were trace-labeled with indium-111 ((111)In), followed by whole-body planar and regional single-photon emission computed tomography (SPECT) imaging at several time points over the course of 10 days.<h4>Results</h4>Nineteen patients were enrolled. (111)In2015-01-01T00:00:00Z2015 Aug2025-06-01T12:01:41.577Z2019-03-27T02:14:35ZS-EPMC48813742612447710.1200/JCO.2014.60.425610.1200/jco.2014.60.4256